Olymvax Biopharmaceuticals
Pharmaceuticals, 515 E Gregory Dr, Chengdu, Illinois, 61820, United States, 201-500 Employees
Phone Number: +12*********
Who is OLYMVAX BIOPHARMACEUTICALS
Founded in 2009, Olymvax Biopharmaceuticals Inc. is a National High-tech Enterprise, focusing on the R&D, Production and Marketing of human-use vaccines. The factory covers an area of 526...
Read More
-
Headquarters: 515 E Gregory Dr, Chengdu, Illinois, 61820, United States
-
Date Founded: 2009
-
Employees: 201-500
-
Revenue: $1 Billion and Over
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from OLYMVAX BIOPHARMACEUTICALS
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Olymvax Biopharmaceuticals
Answer: Olymvax Biopharmaceuticals's headquarters are located at 515 E Gregory Dr, Chengdu, Illinois, 61820, United States
Answer: Olymvax Biopharmaceuticals's phone number is +12*********
Answer: Olymvax Biopharmaceuticals's official website is https://olymvax.com
Answer: Olymvax Biopharmaceuticals's revenue is $1 Billion and Over
Answer: Olymvax Biopharmaceuticals's SIC: 2836
Answer: Olymvax Biopharmaceuticals's NAICS: 541714
Answer: Olymvax Biopharmaceuticals has 201-500 employees
Answer: Olymvax Biopharmaceuticals is in Pharmaceuticals
Answer: Olymvax Biopharmaceuticals contact info: Phone number: +12********* Website: https://olymvax.com
Answer: Founded in 2009, Olymvax Biopharmaceuticals Inc. is a National High-tech Enterprise, focusing on the R&D, Production and Marketing of human-use vaccines. The factory covers an area of 52666 square meters, with 40,000 square meters GMP facility. Adhering to the business philosophy of "strengthening management, committing to improvement and pursuing the highest quality", Olymvax aims to be an internationally well-known and domestically leading vaccine supplier. The construction and management of the production infrastructure conforms to Chinese GMP 2010, and is designed following Euro-American advanced criteria, preparing for the global marketing of products. When it comes to R&D, Olymvax has set up an international strategy on business development and initiated various projects around this goal. Up to date, the company has cooperated with entities with strong scientific ability around the world to develop both first-in -class vaccines and vaccines most in need. Olymvax is keeping integrating global resources, maintaining cooperation with all parties, striving to achieve technological breakthroughs for the development of vaccines. By now Olymvax has sucessfully launched 2 products, Tetanus vaccine and Haemophilus influenzae b vaccine. Still numerous vaccines are in the pipeline, including recombinant Staphylococcus Aureus Vaccine,which is in a phase II clinical trail and Group A Streptococcus Vaccine, as well as Streptococcus pneumoniae vaccine, pertussis vaccine etc.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month